Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy

British Journal of Haematology

Volumn 164, Issue 6, 2014, Pages 894-896

  Starck, Michael ^a   Wendtner, Clemens Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Eculizumab; Gemcitabine; Plasma exchange; Rituximab; Thrombotic microangiopathy

Indexed keywords

ECULIZUMAB; FRESH FROZEN PLASMA; GEMCITABINE; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; ASIAN; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DUODENUM CANCER; ERYTHROCYTE COUNT; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOLYTIC ANEMIA; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LIVER METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; OFF LABEL DRUG USE; PLASMAPHERESIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

EID: 84896720807     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12686     Document Type: Article

References (9)

1. Bharthuar, A., Egloff, L., Becker, J., George, M., Lohr, J.W., Deeb, G. & Iyer, R.V. (2009) Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: A case report. Cancer Chemotherapy and Pharmacology, 64, 177-181.
2. Dasanu, C.A. (2008) Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opinion on Drug Safety, 7, 703-716.
3. Flombaum, C.D., Mouradian, J.A., Caspar, E.S., Erlandson, R.A. & Benedetti, F. (1999) Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. American Journal of Kidney Diseases, 33, 555-562.
4. Gore, E.M., Jones, B.S. & Marques, M.B. (2009) Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? Journal of Clinical Apheresis, 24, 209-214.
5. Gourley, B.L., Mesa, H. & Gupta, P. (2010) Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemotherapy and Pharmacology, 65, 1001-1004.
6. Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nürnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T. & Loirat, C. (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. The New England Journal of Medicine, 368, 2169-2181.
7. Scully, M., Hunt, B.J., Benjamin, S., Liesner, R., Rose, P., Peyvandi, F., Cheung, B., Machin, S.J. & on behalf of British Committee for Standards in Haematology (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 158, 323-335.
8. Taylor, C.M., Machin, S., Wigmore, S.J., Goodship, T.H.J. & on behalf of a working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society (2010) Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom. British Journal of Haematology, 148, 37-47.
9. Zupancic, M., Shah, P.C. & Shah-Khan, F. (2007) Gemcitabine-associated thrombotic thrombocytopenic purpura. The Lancet Oncology, 8, 634-641.